Bcr-Abl tyrosine-kinase inhibitors (TKI) are the first-line therapy for most patients with chronic myelogenous leukemia (CML).A chromosomal abnormality that results in the formation of a so-called Philadelphia chromosome is the root cause of more than 90% of CML cases. This abnormality results from the fusion of the break point cluster (Bcr) gene at chromosome 22 with the Abelson (Abl) tyrosine kinase gene at chromosome 9, creating a chimeric oncogene (Bcr-Abl) and a constitutively active Bcr-Abl tyrosine kinase that has been linked to the pathogenesis of CML. The tyrosine kinase has been selectively inhibited by substances.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V81414 | SNIPER(ABL)-050 | SNIPER(ABL)-050, which is composed of Imatinib (ABL inhibitor) and MV-1 (IAP ligand) through a linker, can effectively degrade BCR-ABL protein. | |
|
V10992 | Tyrphostin AG 957 | 140674-76-6 | AG957 (Tyrphostin AG957; NSC 654705) is a tyrosine kinase inhibitor (TKI) (antagonist) with anti-BCR/ABL tyrosine kinase activity. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
